Structure Therapeutics
GPCR
38 hedge funds and large institutions have $346M invested in Structure Therapeutics in 2023 Q1 according to their latest regulatory filings, with 38 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
13.45% more ownership
Funds ownership: 0% → 13.45% (+13%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $46K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$62.2M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$41.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$29.4M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$24.7M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$22.1M |
Top Sellers
GPCR Hedge Fund Activity: Q1 2023 in Review
38 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Structure Therapeutics (GPCR) for Q1 2023, worth a combined $346M.
Buyers outnumbered sellers: 38 funds opened new GPCR positions and 0 closed out — a net gain of 38 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $62.2M.
- 38 institutional investors held Structure Therapeutics (GPCR) as of Q1 2023, up from 0 in Q4 2022.
- Funds reported $346M of Structure Therapeutics stock for Q1 2023.
- 38 funds opened new Structure Therapeutics positions in Q1 2023 and 0 closed out, a net change of +38 holders.
- The largest Structure Therapeutics buyer in Q1 2023 was Deep Track Capital, an estimated $62.2M added.
Based on aggregated 13F filings for Q1 2023.